Teva says hoping to launch EpiPen-like device by 2018 in U.S.

(Reuters) - Teva Pharmaceutical Industries Ltd on Friday said it hopes to win U.S. approval by late 2017 or early 2018 for its version of Mylan NV's EpiPen device to treat severe allergic reactions, a move that could challenge the branded product's overwhelming dominance.